IPF treatment shows early promise in trial for reversing scarring
IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.| Pulmonary Fibrosis News
IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.| Pulmonary Fibrosis News
Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Looking for information about pulmonary rehabilitation for pulmonary fibrosis (PF)? Read about it here.| Pulmonary Fibrosis News
Learn more about the tests and examinations used to reach a diagnosis of pulmonary fibrosis, which is characterized by scarring in the lungs.| Pulmonary Fibrosis News
Read about the different factors that can cause pulmonary fibrosis.| Pulmonary Fibrosis News
Read about idiopathic pulmonary fibrosis (IPF) — its risk factors, symptoms, and current ways of treating this interstitial lung disease.| Pulmonary Fibrosis News
Learn about familial pulmonary fibrosis, a rare form of pulmonary fibrosis, including its symptoms, diagnosis, risk factors, and treatment.| Pulmonary Fibrosis News
GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells to treat IPF.| Pulmonary Fibrosis News
Pulmonary fibrosis is a disease marked by scarring — or fibrosis — of tissue deep in the lungs, making breathing difficult.| Pulmonary Fibrosis News
